[go: up one dir, main page]

CY1110620T1 - Μεθοδος θεραπειας οξειας παραρρινοκολπιτιδας - Google Patents

Μεθοδος θεραπειας οξειας παραρρινοκολπιτιδας

Info

Publication number
CY1110620T1
CY1110620T1 CY20101100378T CY101100378T CY1110620T1 CY 1110620 T1 CY1110620 T1 CY 1110620T1 CY 20101100378 T CY20101100378 T CY 20101100378T CY 101100378 T CY101100378 T CY 101100378T CY 1110620 T1 CY1110620 T1 CY 1110620T1
Authority
CY
Cyprus
Prior art keywords
pararrinokolpitidas
acute
treatment
disease
treating
Prior art date
Application number
CY20101100378T
Other languages
English (en)
Inventor
Melvyn Bloom
Melvyn Danzig
Patricia Rohane
Heribert Staudinger
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34825945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1110620(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of CY1110620T1 publication Critical patent/CY1110620T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Adhesives Or Adhesive Processes (AREA)

Abstract

Αποκαλύπτονται μέθοδοι θεραπείας παραρρινοκολπίτιδας των ανώτερων αεραγωγών σε ασθενείς που προσβλήθηκαν με την εν λόγω νόσο, η οποία περιλαμβάνει χορήγηση τουλάχιστον μια φορά τη μέρα στις επιφάνειες των εν λόγων αεραγωγών των εν λόγω ασθενών μιας ποσότητας αερολυμένων σωματιδίων φουροϊκής μομεταζόνης ως μια αποτελεσματική μονοθεραπεία για τη θεραπευτική αγωγή της εν λόγω νόσου.
CY20101100378T 2004-01-21 2010-04-28 Μεθοδος θεραπειας οξειας παραρρινοκολπιτιδας CY1110620T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53783004P 2004-01-21 2004-01-21
EP05711867A EP1711164B1 (en) 2004-01-21 2005-01-19 Method of treating acute rhinosinusitis

Publications (1)

Publication Number Publication Date
CY1110620T1 true CY1110620T1 (el) 2015-04-29

Family

ID=34825945

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100378T CY1110620T1 (el) 2004-01-21 2010-04-28 Μεθοδος θεραπειας οξειας παραρρινοκολπιτιδας

Country Status (16)

Country Link
US (2) US20050186144A1 (el)
EP (2) EP1711164B1 (el)
JP (2) JP4976139B2 (el)
AT (1) ATE461693T1 (el)
CA (1) CA2554064A1 (el)
CY (1) CY1110620T1 (el)
DE (1) DE602005020113D1 (el)
DK (1) DK1711164T3 (el)
ES (2) ES2340777T3 (el)
HR (1) HRP20100208T8 (el)
MX (1) MXPA06008240A (el)
PL (1) PL1711164T3 (el)
PT (1) PT1711164E (el)
RS (1) RS51335B (el)
SI (1) SI1711164T1 (el)
WO (1) WO2005072704A2 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072704A2 (en) * 2004-01-21 2005-08-11 Schering Corporation Method of treating acute rhinosinusitis
EP2083798A1 (en) * 2006-10-19 2009-08-05 Cipla Limited Pharmaceutical compositions and nasal spray incorporating anhydrous mometasone furoate
RU2407558C1 (ru) * 2009-07-02 2010-12-27 Федеральное государственное учреждение "Российский научный центр восстановительной медицины и курортологии Федерального агентства по здравоохранению и социальному развитию РФ" (ФГУ "РНЦВМиК Росздрава") Способ лечения острого риносинусита у детей
TWI411121B (zh) * 2010-03-11 2013-10-01 Ind Tech Res Inst 光吸收層之製造方法及應用其之太陽能電池結構
EP3789022A1 (en) * 2012-12-27 2021-03-10 Massachusetts Eye & Ear Infirmary Treatment of rhinosinusitis with p-glycoprotein inhibitors
JP7085485B2 (ja) 2016-01-15 2022-06-16 マサチューセッツ アイ アンド イヤー インファーマリー 分泌型ｐ－糖タンパク質は、慢性鼻副鼻腔炎の非侵襲的バイオマーカーである
US12295933B2 (en) 2019-03-25 2025-05-13 Massachusetts Eye And Ear Infirmary Methods and compositions to treat and diagnose diseases or pathologies associated with inflammation of the sinuses and nasal cavity
CN116209449A (zh) * 2020-06-21 2023-06-02 麻省眼耳科医院 用于慢性鼻窦炎治疗的维拉帕米和莫米松联合疗法
JP2024049405A (ja) * 2021-02-22 2024-04-10 興和株式会社 新規吸入剤
EP4566595A1 (en) * 2023-12-07 2025-06-11 Bernhard Roth Combination preparation for the treatment of acute and chronic rhinosinusitis

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1359A (en) 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
US4731447A (en) 1985-05-13 1988-03-15 Schering Corporation Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof
US4873335A (en) * 1986-03-12 1989-10-10 Schering Corporation 3-phenethyl-2-benzene-amides or aza-derivatives thereof
CZ271493A3 (en) 1991-06-10 1994-07-13 Schering Corp Aerosol preparations without chlorofluorinated hydrocarbons
ZA924163B (en) * 1991-06-10 1993-02-24 Schering Corp Non-chlorofluorocarbon aerosol formulations
US6127353A (en) 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US6068832A (en) 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
US5837713A (en) * 1997-02-26 1998-11-17 Mayo Foundation For Medical Education And Research Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids
US6503537B2 (en) * 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
US6187765B1 (en) 1997-10-09 2001-02-13 Schering Corporation Mometasone furoate suspensions for nebulization
US6297227B1 (en) * 1998-09-10 2001-10-02 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
SE9803770D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Dry powder pharmaceutical formulation
US6465581B1 (en) * 2001-01-24 2002-10-15 The Goodyear Tire & Rubber Company Silica reinforced rubber composition which contains stabilized unsymmetrical coupling agents and article of manufacture, including a tire, having at least one component comprised of such rubber composition
AR036358A1 (es) * 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
ES2281691T3 (es) * 2002-08-23 2007-10-01 Schering Corporation Composiciones farmaceuticas.
US20040081625A1 (en) * 2002-10-21 2004-04-29 Schering Corporation Nasal formulations for the treatment of allergies
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US20040235807A1 (en) * 2003-05-21 2004-11-25 Weinrich Karl P. Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
AU2004285447A1 (en) * 2003-10-20 2005-05-12 Schering Corporation Pharmaceutical compositions
WO2005072704A2 (en) * 2004-01-21 2005-08-11 Schering Corporation Method of treating acute rhinosinusitis
WO2012082735A1 (en) 2010-12-13 2012-06-21 Nanostim, Inc. Delivery catheter systems and methods
US9106249B1 (en) 2014-09-04 2015-08-11 Semtech Corporation Calibration of a time-interleaved analog-to-digital converter

Also Published As

Publication number Publication date
US20090022671A1 (en) 2009-01-22
EP1711164A2 (en) 2006-10-18
JP4976139B2 (ja) 2012-07-18
MXPA06008240A (es) 2006-08-31
HRP20100208T1 (hr) 2010-05-31
WO2005072704A3 (en) 2006-07-20
US20050186144A1 (en) 2005-08-25
CA2554064A1 (en) 2005-08-11
DK1711164T3 (da) 2010-07-19
EP2201936B1 (en) 2013-06-19
DE602005020113D1 (de) 2010-05-06
JP2007518817A (ja) 2007-07-12
WO2005072704A2 (en) 2005-08-11
ES2426957T3 (es) 2013-10-28
ATE461693T1 (de) 2010-04-15
ES2340777T3 (es) 2010-06-09
PL1711164T3 (pl) 2010-09-30
SI1711164T1 (sl) 2010-06-30
EP2201936A1 (en) 2010-06-30
RS51335B (sr) 2011-02-28
PT1711164E (pt) 2010-06-28
EP1711164B1 (en) 2010-03-24
JP2008110991A (ja) 2008-05-15
HRP20100208T8 (hr) 2010-06-30

Similar Documents

Publication Publication Date Title
CY1110620T1 (el) Μεθοδος θεραπειας οξειας παραρρινοκολπιτιδας
WO2006078463A3 (en) Method for treating cardiovascular disease
HUS1700012I1 (hu) Bruton-tirozinkináz inhibitorok
EA201000914A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
PT2420234E (pt) 1h-benzimidazole-4-carboxamidas substituídas com um carbono quaternário na posição 2 como inibidores de parp para uso no tratamento do cancro
LU92232I2 (fr) "Florbétapir (18 F)"
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
BRPI0418745A (pt) anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente
WO2006085149A3 (en) Methods and compositions for treating amyloid-related diseases
ATE530519T1 (de) Cyclobutylaminderivate
CY1112397T1 (el) Συνδυασμενη θεραπεια για την αντιμετωπιση του καρκινου
PT2383271E (pt) Aminoquinolonas como inibidores de gsk-3
DK1505990T3 (da) Fremgangsmåder til behandling af hepatitis
PL2380584T3 (pl) Sposób do immunostymulacji
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
DK1715890T3 (da) CTGF som mål for mikroalbuminuriterapi hos patienter med diabetisk nefropati
TW200740441A (en) Methods and reagents for the treatment of inflammatory disorders
WO2008019388A3 (en) Milnacipran for the treatment of fatigue associated with fibromyalgia syndrome
WO2006078713A3 (en) Methotrexate combinations for treating inflammatory diseases
ATE527997T1 (de) Verwendung von aminapthon zur herstellung eines medikaments zur behandlung von arteriopathien
BRPI0503827A (pt) métodos para prevenir ou tratar infecções respiratórias em lactentes
WO2008016665A3 (en) Imidazoacridine compounds for treating flt3 -mediated disorders
RU2007103667A (ru) Способ лечения псориаза
DK1732648T3 (da) Sygdomsbehandling
WO2008036157A3 (en) Prophylactic and therapeutic treatment of avian influenza infections in animals